Bioxyne Limited (ASX: BXN) regularly hosts investor and stakeholder webinars to provide timely updates on our performance, strategic initiatives, and key developments across the business. Below you can access recordings of recent presentations, offering insight into our progress and ongoing commitment to transparency and engagement with shareholders.

Bioxyne Limited (ASX: BXN) is committed to maintaining the highest standards of corporate governance, transparency, and ethical conduct across all aspects of its operations. The following governance documents outline the Company’s core policies and principles that guide its leadership, decision-making processes, and stakeholder responsibilities.

At Bioxyne Limited, we are committed to maintaining transparent and timely communication with our shareholders, investors, and partners.
Below you will find answers to some of the most frequently asked questions regarding our corporate structure, governance, financial reporting, and investor services.
This section is designed to provide clear and accessible information about the Company and its operations.

At Bioxyne, innovation and transparency are at the heart of everything we do.
Our news and announcements highlight the milestones, partnerships, and scientific advancements driving our expansion in the life sciences industry.
Stay up to date with the stories shaping Bioxyne’s journey as an international health and wellness leader.

This section provides current and historical information on Bioxyne Limited’s (ASX: BXN) share price as quoted on the Australian Securities Exchange.
Shareholders and investors can use this resource to track the Company’s market performance, review recent trading activity, and access key market data.
All information is updated regularly in accordance with ASX reporting standards.

As part of our ongoing commitment to transparency, Bioxyne Limited publishes all market-sensitive information through the Australian Securities Exchange (ASX).
In this section, you’ll find the Company’s official announcements, financial disclosures, and investor communications that reflect our continued growth and global strategy in the life sciences sector.

Name

Bioxyne Limited Business

Description

Bioxyne Limited (ASX:BXN) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. Bioxyne and wholly owned subsidiary Breathe Life Sciences manufacture and distribute novel medicines (cannabis, MDMA, Psilocybin) and consumer health products (CBD, functional mushrooms, other) in Australia, Europe, UK, Japan, and USA. In Australia, Breathe Life Sciences holds a TGA manufacturing license, controlled substance licenses to import, export, and wholesale Schedule 3,4, 8 and 9 products, operating primarily business to business. Outside of Australia, the business has manufacturing and distribution centres in Japan, the UK, and Europe, and operates direct to consumer supply of its trademarked Dr Watson® brand. For more information on Bioxyne, please visit https://bioxyne.com

Shares on Issue

Ordinary shares: 2,053,312,000
Performance Rights 26,666,667

Listings

ASX

Managing Director and Chief Executive Officer

Mr Samuel Watson

Chief Financial Officer

Guy Robertson

Board of Directors

Mr Anthony Ho – Non Executive Chairman
Mr Samuel Watson – Managing Director and CEO
Jason Hine – Executive Director
Company Secretary: Guy Robertson

Registered Office

Suite 506, Level 5 50 Clarence Street Sydney NSW 2000
Phone: + 61 2 9078 8180
Fax: +6102 9078 7661
Email: info@bioxyne.com
Web: http://www.bioxyne.com

Share Registry

Automic Pty Ltd Level 5 126 Phillip Street Sydney NSW 2000
Phone: 1300 288 664
Fax: +61 2 9698 5414
Email: hello@automicgroup.com.au
Web: www.securitytransfer.com.au

Auditor

RSM Australia Partners Level 13, 60 Castlereagh Street Sydney NSW 2000
Phone: +61 2 8226 4500

Bioxyne / Breathe Life Sciences (BLS)

Bioxyne Limited (ASX:BXN) is an Australian life sciences and health products business. In June 2023  Bioxyne acquired BLS in an all shares transaction becoming the parent company of Breathe Life Sciences (“BLS”) and DR Watson®.  The Group, which is headquartered in Sydney and has offices in London, Manchester, Prague, Brisbane, and Nagoya,  manufactures and distributes novel pharmaceuticals and consumer health products globally.

BLS’ focus is in the development and commercialisation of medical cannabis, psychedelics, and novel foods and consumer health products under our own brands and manufacturing for third party brands.

BLS’ goal is to become the market leading Australian manufacturer of novel pharmaceuticals and medicine products derived from Cannabis, Psilocybe Cubensis, and MDMA.

In Australia, BLS is licensed to manufacture MDMA and Psilocybin products for commercial supply to authorised prescribers and clinical trials in Australia and global export markets. BLS was the first Australian company to receive its GMP license to manufacture MDMA and Psilocybin, and as of July 2024, remains the only licensed manufacturer in the country.

In the UK and Europe BLS is a market leader in the supply of CBD (Cannabidiol) and functional mushroom products to national retailers and Amazon. BLS manufactures private, white label, and its in house brands in its UK and EU facilities.

In the USA Bioxyne is currently selling PCC® to Nu-Skin Enterprises (USA) as the active ingredient in ProBio PCC™, and PCC® is being used in a number of other products currently sold in Europe and North America.

The Bioxyne team has extensive skills and knowledge in developing and commercialising life sciences technologies, health products and medicines. The Bioxyne board and management, backed by a supportive shareholder base, is positioned to pursue new growth opportunities for our products in Australasia, Europe, Asia and the USA.

DR Watson®

The Dr Watson brand was established in 2019 when it launched  its range of CBD lifestyle and consumer health products in the UK and Japan. In 2022 Dr Watson launched its medical cannabis range in Australia, supplying wholesale to pharmacies and clinics around the country. The Dr Watson product catalogue extends across multiple dose forms from pastilles (gummies), vape, oral mucosal oils, flower, and suppositories.

Probiotic PCC^®

Bioxyne’s proprietary and clinically tested probiotic is Lactobacillus fermentum VRI-003 (PCC®). PCC® is supported by several clinical trials which describe its ability to boost immune and gastrointestinal health. The probiotic development is supported by a manufacturing agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of probiotics and other dietary supplement products for the food, health, pharmaceutical and agriculture industries.

Bioxyne’s probiotic sales are led by ProBio PCC™, a probiotic product containing PCC® sold globally exclusively by Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who offers only quality solutions to their customers.

Bioxyne sells its own branded PCC®-containing products in Australia: Progastrim® for gut and immune health and proTract® for atopic dermatitis (eczema).

Bioxyne is actively pursuing new opportunities in the immune health sector that will enhance future value for its shareholders. These include further clinical studies to develop new products to expand product range and to support the marketing of current products.